Direct Oral Anticoagulant Monitoring In The ICU: Clinical Utility And Limitations Of Anti-XA Levels In Unstable Physiology

References

[1] Billoir, P., Elie, T., Levy, J. H., Besnier, E., Dureuil, B., Veber, B., … Clavier, T. (2022). Anticoagulation monitoring with activated partial thromboplastin time and anti-Xa activity in intensive care unit patients: Interest of thrombin generation assay. International Journal of Molecular Sciences, 23(19), 11219. https://doi.org/10.3390/ijms231911219

[2] Benes, J., Skulec, R., Jobanek, J., & Cerny, V. (2022). Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study. Biomedical Papers of the Medical Faculty of Palacky University in Olomouc, 166(2), 1–8. https://doi.org/10.5507/bp.2022.040

[3] De Caterina, R., Husted, S., Wallentin, L., De Caterina, R., Husted, S., Andreotti, F., … Weitz, J. I. (2012). New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease position paper. Journal of the American College of Cardiology, 59(16), 1413–1425. https://doi.org/10.1016/j.jacc.2011.11.031

[4] Gilbert, B. W., Reeder, J. A., Reynolds, T. R., Tabaka, C. A., & Rech, M. A. (2022). Anticoagulation monitoring in the intensive care unit. Critical Care Nursing Quarterly, 45(2), 108–118. https://doi.org/10.1097/CNQ.0000000000000385

[5] Jayaram, K. (2022). Monitoring anticoagulation. In Transfusion Practice in Clinical Neurosciences (pp. 417–429). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-16-9943-0_30

[6] Johnson, D., Subhas, S., & Rowden, A. (2011). 794: Assessment of a heparin nomogram utilizing anti-Xa monitoring in critically ill patients with acute DVT/PE. Critical Care Medicine, 39(12), 223. https://doi.org/10.1097/01.ccm.0000410660.12345.78

[7] Kumano, O., Akatsuchi, K., & Amiral, J. (2021). Updates on anticoagulation and laboratory tools for therapy monitoring of heparin, vitamin K antagonists and direct oral anticoagulants. Biomedicines, 9(3), 264. https://doi.org/10.3390/biomedicines9030264

[8] Lage, S., Carvalho, R., Kopel, L., Ribeiro, M., Bastos, J., Fagundes Jr, A., … Garbes-Netto, P. (2006). Use of anti-Xa factor titration as efficacy marker of enoxaparin in critically ill patients. Critical Care, 10(Suppl 1), P161. https://doi.org/10.1186/cc4920

[9] Levy, J. H., Spyropoulos, A. C., Samama, C. M., & Douketis, J. (2014). Direct oral anticoagulants: New drugs and new concepts. JACC: Cardiovascular Interventions, 7(12), 1333–1351. https://doi.org/10.1016/j.jcin.2014.07.014

[10] Mallett, S. V., Chowdary, P., & Burroughs, A. K. (2013). Clinical utility of viscoelastic tests of coagulation in patients with liver disease. Liver International, 33(7), 961–974. https://doi.org/10.1111/liv.12106

[11] Monagle, P., & Newall, F. (2018). Management of thrombosis in children and neonates: Practical use of anticoagulants in children. In Hematology 2014, the American Society of Hematology Education Program Book, 2018(1), 399–404. https://doi.org/10.1182/asheducation-2018.1.399

[12] Moussa, M. D., Soquet, J., Lamer, A., Labreuche, J., Gantois, G., Dupont, A., … Robin, E. (2021). Evaluation of anti-activated factor X activity and activated partial thromboplastin time relations and their association with bleeding and thrombosis during veno-arterial ECMO support: A retrospective study. Journal of Clinical Medicine, 10(10), 2158. https://doi.org/10.3390/jcm10102158

[13] O’Leary, J. G., Greenberg, C. S., Patton, H. M., & Caldwell, S. H. (2019). AGA clinical practice update: Coagulation in cirrhosis. Gastroenterology, 157(1), 34–43. https://doi.org/10.1053/j.gastro.2019.03.009

[14] Pavoni, V., Gianesello, L., Conti, D., Ballo, P., Dattolo, P., Prisco, D., & Görlinger, K. (2022). “In less than no time”: Feasibility of rotational thromboelastometry to detect anticoagulant drugs activity and to guide reversal therapy. Journal of Clinical Medicine, 11(5), 1407. https://doi.org/10.3390/jcm11051407

[15] Rajsic, S., Breitkopf, R., Bachler, M., & Treml, B. (2021). Diagnostic modalities in critical care: Point-of-care approach. Diagnostics, 11(12), 2202. https://doi.org/10.3390/diagnostics11122202

[16] Stach, Z., Valenta, J., Salaj, P., Hrachovinova, I., Marinov, I., & Stritesky, M. (2006). Continuous administration of LMWH in critical patients: A contribution to the monitoring of hemocoagulation. Critical Care, 10(Suppl 1), P162. https://doi.org/10.1186/cc4921

[17] Image retrieved from Springer Nature (n.d.). [Figure 3 from “Anticoagulant therapy in pulmonary embolism?”]. Springer Nature. https://media.springernature.com/full/springer-static/image/art%3A10.1007%2Fs11239-015-1310-7/MediaObjects/11239_2015_1310_Fig3_HTML.gif?as=webp

[18] Schwarb, H. (2016). New direct oral anticoagulants (DOAC) and their use today. Dentistry, 4, 5. https://doi.org/10.3390/dentistry-04-00005

[19] [Diagram of coagulation cascade with DOAC targets] [Online image]. (n.d.). Taylor & Francis Online. https://www.tandfonline.com/cms/asset/3d1f0a6d-2fdf-481c-8043-bc87bd1b4916/iemt_a_2287472_f0001_oc.jpg

[20] Abdul Wahab, N., Patnaik, R., & Gurjar, M. (2021). Use of direct oral anticoagulants in ICU patients. Part II – Clinical evidence. Anaesthesiology Intensive Therapy, 53(5), 440–449. https://doi.org/10.5114/ait.2021.110608

[21] Burnett, A. E., Mahan, C. E., Vazquez, S. R., Oertel, L. B., Garcia, D. A., & Ansell, J. (2016). Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. Journal of Thrombosis and Thrombolysis, 41(2), 206–232. https://doi.org/10.1007/s11239-015-1310-7

@article{1712947,
      author = {Nhan Hoang},
      title = {Direct Oral Anticoagulant Monitoring In The ICU: Clinical Utility And Limitations Of Anti-XA Levels In Unstable Physiology},
      journal = {Iconic Research And Engineering Journals},
      year = {2023},
      volume = {7},
      number = {3},
      pages = {856-866},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1712947.pdf},
      abstract = {Direct oral anticoagulants work well in stable patients because they have predictable effects and usually do not need routine tests. In the ICU, the situation is very different. Critical illness changes how the body absorbs and clears medication, and treatments like vasopressors, dialysis, and ECMO can affect drug levels. This makes it hard to know how much anticoagulant effect a patient actually has. Because the usual blood tests do not reflect DOAC activity, many hospitals use anti Xa assays to check whether the drug is still active. These tests can be helpful during emergencies, such as active bleeding, urgent surgery, suspected overdose, or severe kidney failure. They give clinicians a sense of whether DOAC effects are present. However, anti Xa levels are not perfect in the ICU. Organ failure, fluid shifts, inflammation, and various supportive therapies can make the results unreliable. A level may not always match the patient?s true risk of bleeding or clotting, so the test should be used only as a guide and always interpreted alongside the clinical picture. This article explains when anti Xa testing can be useful in the ICU, what its limitations are, and how it can support better decision making in critically ill patients.},
      keywords = {DOACs, AntiXa, ICU, Criticalillness, Unstablephysiology, Renaldysfunction, Bleedingrisk, Thrombosis, Extracorporeal, Absorption, Anticoagulation},
      month = {September},
  }